vs
BIOCRYST PHARMACEUTICALS INC（BCRX）与LiveRamp Holdings, Inc.（RAMP）财务数据对比。点击上方公司名可切换其他公司
BIOCRYST PHARMACEUTICALS INC的季度营收约是LiveRamp Holdings, Inc.的1.9倍（$406.6M vs $212.2M），BIOCRYST PHARMACEUTICALS INC净利率更高（60.5% vs 18.8%，领先41.7%），BIOCRYST PHARMACEUTICALS INC同比增速更快（209.1% vs 8.6%），过去两年BIOCRYST PHARMACEUTICALS INC的营收复合增速更高（109.4% vs 11.1%）
BioCryst Pharmaceuticals是一家总部位于美国北卡罗来纳州达勒姆的制药企业，属于后期发展阶段的生物科技公司，聚焦于治疗罕见重症的口服药物研发。其研发的抗病毒药物帕拉米韦（商品名Rapivab）于2014年12月获得美国FDA批准，此后也陆续在日本、韩国与中国获批上市。
LiveRamp Holdings, Inc.是一家美国SaaS企业，核心业务为提供数据连接平台，服务涵盖数据导入、线下数据线上迁移等能力，助力企业开展营销相关的数据应用，为品牌及营销从业者的数字化运营提供技术支撑。
BCRX vs RAMP — 直观对比
营收规模更大
BCRX
是对方的1.9倍
$212.2M
营收增速更快
BCRX
高出200.5%
8.6%
净利率更高
BCRX
高出41.7%
18.8%
两年增速更快
BCRX
近两年复合增速
11.1%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $406.6M | $212.2M |
| 净利润 | $245.8M | $39.9M |
| 毛利率 | 97.7% | 71.9% |
| 营业利润率 | 64.0% | 18.6% |
| 净利率 | 60.5% | 18.8% |
| 营收同比 | 209.1% | 8.6% |
| 净利润同比 | 1017.5% | 255.7% |
| 每股收益（稀释后） | $1.13 | $0.62 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BCRXRAMP
| Q4 25 | $406.6M | $212.2M | ||
| Q3 25 | $159.4M | $199.8M | ||
| Q2 25 | $163.4M | $194.8M | ||
| Q1 25 | $145.5M | $188.7M | ||
| Q4 24 | $131.5M | $195.4M | ||
| Q3 24 | $117.1M | $185.5M | ||
| Q2 24 | $109.3M | $176.0M | ||
| Q1 24 | $92.8M | $171.9M |
净利润BCRXRAMP
| Q4 25 | $245.8M | $39.9M | ||
| Q3 25 | $12.9M | $27.4M | ||
| Q2 25 | $5.1M | $7.7M | ||
| Q1 25 | $32.0K | $-6.3M | ||
| Q4 24 | $-26.8M | $11.2M | ||
| Q3 24 | $-14.0M | $1.7M | ||
| Q2 24 | $-12.7M | $-7.5M | ||
| Q1 24 | $-35.4M | $-5.4M |
毛利率BCRXRAMP
| Q4 25 | 97.7% | 71.9% | ||
| Q3 25 | 98.6% | 70.2% | ||
| Q2 25 | 98.3% | 70.1% | ||
| Q1 25 | 96.9% | 69.3% | ||
| Q4 24 | 95.4% | 71.9% | ||
| Q3 24 | 97.3% | 72.4% | ||
| Q2 24 | 98.4% | 70.6% | ||
| Q1 24 | 98.6% | 72.2% |
营业利润率BCRXRAMP
| Q4 25 | 64.0% | 18.6% | ||
| Q3 25 | 18.6% | 10.7% | ||
| Q2 25 | 18.2% | 3.7% | ||
| Q1 25 | 14.6% | -6.1% | ||
| Q4 24 | -3.4% | 7.5% | ||
| Q3 24 | 6.6% | 4.0% | ||
| Q2 24 | 8.0% | -3.0% | ||
| Q1 24 | -15.6% | -8.3% |
净利率BCRXRAMP
| Q4 25 | 60.5% | 18.8% | ||
| Q3 25 | 8.1% | 13.7% | ||
| Q2 25 | 3.1% | 4.0% | ||
| Q1 25 | 0.0% | -3.3% | ||
| Q4 24 | -20.4% | 5.7% | ||
| Q3 24 | -12.0% | 0.9% | ||
| Q2 24 | -11.6% | -4.3% | ||
| Q1 24 | -38.1% | -3.1% |
每股收益（稀释后）BCRXRAMP
| Q4 25 | $1.13 | $0.62 | ||
| Q3 25 | $0.06 | $0.42 | ||
| Q2 25 | $0.02 | $0.12 | ||
| Q1 25 | $0.00 | $-0.10 | ||
| Q4 24 | $-0.13 | $0.17 | ||
| Q3 24 | $-0.07 | $0.03 | ||
| Q2 24 | $-0.06 | $-0.11 | ||
| Q1 24 | $-0.17 | $-0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $274.7M | $403.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-119.2M | $962.3M |
| 总资产 | $514.2M | $1.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BCRXRAMP
| Q4 25 | $274.7M | $403.4M | ||
| Q3 25 | $212.9M | $376.9M | ||
| Q2 25 | $260.0M | $371.1M | ||
| Q1 25 | $295.1M | $420.8M | ||
| Q4 24 | $320.9M | $384.3M | ||
| Q3 24 | $96.8M | $348.4M | ||
| Q2 24 | $78.4M | $342.7M | ||
| Q1 24 | $84.3M | $368.9M |
股东权益BCRXRAMP
| Q4 25 | $-119.2M | $962.3M | ||
| Q3 25 | $-387.9M | $943.8M | ||
| Q2 25 | $-421.6M | $947.8M | ||
| Q1 25 | $-451.9M | $948.9M | ||
| Q4 24 | $-475.9M | $957.7M | ||
| Q3 24 | $-468.6M | $932.1M | ||
| Q2 24 | $-475.6M | $951.9M | ||
| Q1 24 | $-476.2M | $949.1M |
总资产BCRXRAMP
| Q4 25 | $514.2M | $1.3B | ||
| Q3 25 | $446.4M | $1.2B | ||
| Q2 25 | $457.2M | $1.2B | ||
| Q1 25 | $480.0M | $1.3B | ||
| Q4 24 | $490.4M | $1.3B | ||
| Q3 24 | $491.3M | $1.2B | ||
| Q2 24 | $472.4M | $1.2B | ||
| Q1 24 | $467.9M | $1.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $292.0M | — |
| 自由现金流经营现金流 - 资本支出 | $291.2M | — |
| 自由现金流率自由现金流/营收 | 71.6% | — |
| 资本支出强度资本支出/营收 | 0.2% | 0.1% |
| 现金转化率经营现金流/净利润 | 1.19× | — |
| 过去12个月自由现金流最近4个季度 | $344.9M | — |
8季度趋势，按日历期对齐
经营现金流BCRXRAMP
| Q4 25 | $292.0M | — | ||
| Q3 25 | $41.6M | $57.4M | ||
| Q2 25 | $41.3M | $-15.8M | ||
| Q1 25 | $-27.5M | — | ||
| Q4 24 | $-5.2M | $45.1M | ||
| Q3 24 | $8.2M | $55.6M | ||
| Q2 24 | $-1.4M | $-9.3M | ||
| Q1 24 | $-53.7M | — |
自由现金流BCRXRAMP
| Q4 25 | $291.2M | — | ||
| Q3 25 | $40.3M | $56.8M | ||
| Q2 25 | $41.1M | $-16.2M | ||
| Q1 25 | $-27.7M | — | ||
| Q4 24 | $-5.9M | $44.8M | ||
| Q3 24 | $8.2M | $55.4M | ||
| Q2 24 | $-1.5M | $-9.6M | ||
| Q1 24 | $-53.9M | — |
自由现金流率BCRXRAMP
| Q4 25 | 71.6% | — | ||
| Q3 25 | 25.3% | 28.4% | ||
| Q2 25 | 25.2% | -8.3% | ||
| Q1 25 | -19.0% | — | ||
| Q4 24 | -4.5% | 22.9% | ||
| Q3 24 | 7.0% | 29.8% | ||
| Q2 24 | -1.4% | -5.4% | ||
| Q1 24 | -58.1% | — |
资本支出强度BCRXRAMP
| Q4 25 | 0.2% | 0.1% | ||
| Q3 25 | 0.8% | 0.3% | ||
| Q2 25 | 0.1% | 0.2% | ||
| Q1 25 | 0.1% | 0.2% | ||
| Q4 24 | 0.5% | 0.1% | ||
| Q3 24 | 0.1% | 0.1% | ||
| Q2 24 | 0.1% | 0.1% | ||
| Q1 24 | 0.3% | 1.0% |
现金转化率BCRXRAMP
| Q4 25 | 1.19× | — | ||
| Q3 25 | 3.23× | 2.09× | ||
| Q2 25 | 8.12× | -2.04× | ||
| Q1 25 | -859.91× | — | ||
| Q4 24 | — | 4.02× | ||
| Q3 24 | — | 32.10× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
